Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ: DXCM )

89.07 +4.98 (+5.92%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
32 33 Next >
Xylem, DexCom And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by around 0.4% on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Here's How Much $100 Invested In DexCom 15 Years Ago Would Be Worth Today
Via Benzinga
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive. 
Via InvestorPlace
Wall Street is surprisingly most bullish on these 3 Nasdaq stocks
Analysts are gradually shifting toward underperforming, less prominent names to find the next big thing - including these three current Wall Street faves 
Via MarketBeat
These 2 Growth Stocks Could Soar 33% and 45% According to Wall Street Analysts. Are They Smart Buys Now?
Expectations are high for companies making blood sugar monitors and business automation software. 
Via The Motley Fool
DexCom: Q4 Earnings Insights
Via Benzinga
Prediction: 2 Stocks That Could Trounce the Market
They have done it before. 
Via The Motley Fool
Earnings Scheduled For February 8, 2024
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. 
Via Benzinga
Wall Street's Next Stock-Split Stocks Are Liable to Be Familiar Names
Nine high-profile stocks -- Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk -- have split since mid-2021. Two of these companies appear ready... 
Via The Motley Fool
2 No-Brainer Healthcare Stocks to Buy Right Now
Companies in the healthcare industry tend to generate returns in a wide range of market environments. 
Via The Motley Fool
Continuous Glucose Monitor Maker Dexcom's Q4 Profit Triples On Volume Growth And New Customer Additions
Dexcom's Q4 2023 performance, reporting $1.03 billion sales, $256.3 million profits, and beating estimates. Dexcom projects $4.15-$4.35 billion in 2024 revenues. William Blair affirms Outperform... 
Via Benzinga
DexCom (DXCM) Q4 2023 Earnings Call Transcript
DXCM earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results
From DexCom, Inc.
Via Business Wire
If You Invested $100 In This Stock 15 Years Ago, You Would Have $13,000 Today
Via Benzinga
NASDAQ:DXCM: a strong growth stock preparing for the next leg up?.
DEXCOM INC (NASDAQ:DXCM)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
3 Nasdaq stocks likely to make big earnings splashes
Here we look at a few examples of high beta, high standard deviation Nasdaq-100 stocks that are poised to have volatile earnings moves in the near future. 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
2 Phenomenal Stocks to Buy for the New Year
These growth stocks are raking in profits and cash as leaders in their respective industries. 
Via The Motley Fool
Stryker Stock Sees Relative Strength Rating Jump To 84
The Relative Strength (RS) Rating for Stryker stock jumped into a new percentile Thursday, with a rise from 76 to 84. 
Via Investor's Business Daily
Evaluating NASDAQ:DXCM for Growth Investment Opportunities.
Why the growth investor may take a look at NASDAQ:DXCM. 
Via Chartmill
These 2 Growth Stocks Are Brilliant Buys for the New Year
Business is booming for these stocks, and investors might want to stop and take note. 
Via The Motley Fool
Expert Ratings For DexCom
Via Benzinga
Here's How Much $1000 Invested In DexCom 15 Years Ago Would Be Worth Today
Via Benzinga
Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
Don't overlook NASDAQ:DXCM—a stock with solid growth prospects and a reasonable valuation.
Investors should take note ofDEXCOM INC (NASDAQ:DXCM), a growth stock that remains attractively priced. 
Via Chartmill
MarketBeat ‘Stock of the Week’: Intuitive Surgical hits new highs
With recent obesity drug fears proving to be overblown and equipment placements growing, expect ISRG to reward growth investors with plenty more record highs. 
Via MarketBeat
Topics Earnings
Exposures Financial
3 Mid-Cap Stocks Poised for a Breakout in 2024
Mid-cap stocks are expected to have a breakout year especially in light of their underperformance in 2023 with these equities looking strong. 
Via InvestorPlace
The 3 Best Growth Stocks to Buy in January 2024
The best growth stocks to buy for 2024 with an impressive growth history and solid long-term tailwinds to support 30% EPS growth. 
Via InvestorPlace
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut. 
Via Investor's Business Daily
Topics ETFs
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
Last year wasn't great for either stock, but that's no reason to ignore them. 
Via The Motley Fool
History Says the Nasdaq Will Soar in 2024: 1 Stock-Split AI Growth Stock to Buy Now and Hold Forever
Nvidia is well positioned to create value for patient shareholders, given its leadership in artificial intelligence chips. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.